Top

Published in:

01-02-2024 | Breast Cancer | Breast Oncology

Following the High-Risk Patient: Breast Cancer Risk-Based Screening

Authors: Christine L. Klassen, MD, Lyndsay D. Viers, MD, Karthik Ghosh, MD

Published in: Annals of Surgical Oncology | Issue 5/2024

Abstract

Breast cancer (BC) is the most common cancer occurring in women in the USA today, and accounts for more than 40,000 deaths annually (Giaquinto in CA Cancer J Clin 72: 524–541, 2022). While breast cancer survival has improved over the past decades, incidence has increased, and diagnoses are being made at younger ages. This emphasizes the importance of risk evaluation, accurate prediction, and effective mitigation and risk reduction strategies. Enhanced screening can help detect cancers at an earlier stage, thus improving morbidity and mortality. This review addresses the recognition of women at high-risk for BC and monitoring strategies for those at high risk.

Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41. https://doi.org/10.3322/caac.21754.CrossRefPubMed

Fletcher SW, Elmore JG. Mammographic screening for breast cancer. N Engl J Med. 2003;348(17):1672–80. https://doi.org/10.1056/NEJMcp021804.CrossRefPubMedPubMedCentral

Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575–90. https://doi.org/10.1093/annonc/mdv590.CrossRefPubMed

Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am College Radiol. 2018;15(3):408–14. https://doi.org/10.1016/j.jacr.2017.11.034.CrossRef

Siu AL. Force USPST. Screening for breast cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2016;164(4):279–96. https://doi.org/10.7326/M15-2886.CrossRefPubMed

Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440–51. https://doi.org/10.1056/NEJMoa2005936.CrossRefPubMedPubMedCentral

Collaborative Group on Hormonal Factors in Breast C. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. The Lancet. 2001;358(9291):1389–99. https://doi.org/10.1016/S0140-6736(01)06524-2.CrossRef

Bland KI, Klimberg VS, Copeland EM, Gradishar WJ. The breast: Comprehensive management of benign and malignant diseases. 5th edn. Elsevier; 2018. p. 1114.

Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386–94. https://doi.org/10.1200/JCO.2003.11.059.CrossRefPubMed

10.

Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Nati Compr Cancer Netw. 2018;16(11):1362–89. https://doi.org/10.6004/jnccn.2018.0083.CrossRef

11.

Degnim AC, Visscher DW, Radisky DC, et al. Breast cancer risk by the extent and type of atypical hyperplasia. Cancer. 2016;122(19):3087–8. https://doi.org/10.1002/cncr.30151.CrossRefPubMed

12.

Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses’ Health Study. Cancer. 2007;109(2):180–7. https://doi.org/10.1002/cncr.22408.CrossRefPubMed

13.

Donaldson AR, McCarthy C, Goraya S, et al. Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy. Cancer. 2018;124(3):459–65. https://doi.org/10.1002/cncr.31061.CrossRefPubMed

14.

Brentnall AR, Harkness EF, Astley SM, et al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Res. 2015. https://doi.org/10.1186/s13058-015-0653-5.CrossRefPubMedPubMedCentral

15.

Bodewes FTH, van Asselt AA, Dorrius MD, Greuter MJW, de Bock GH. Mammographic breast density and the risk of breast cancer: a systematic review and meta-analysis. Breast. 2022;66:62–8. https://doi.org/10.1016/j.breast.2022.09.007.CrossRefPubMedPubMedCentral

16.

Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97. https://doi.org/10.3322/caac.21405.CrossRefPubMedPubMedCentral

17.

Amir E, Goodwin PJ. Breast cancer chemoprevention gets personal. J Clin Oncol. 2011;29(17):2296–8. https://doi.org/10.1200/JCO.2011.35.7111.CrossRefPubMed

18.

Bambhroliya A, Chavez-MacGregor M, Brewster AM. Barriers to the use of breast cancer risk reduction therapies. J Natl Compr Cancer Netw. 2015;13(7):927–35. https://doi.org/10.6004/jnccn.2015.0107.CrossRef

19.

Visvanathan K, Fabian CJ, Bantug E, et al. Use of Endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(33):3152–65. https://doi.org/10.1200/JCO.19.01472.CrossRefPubMed

20.

The Hormone Therapy Position Statement of The North American Menopause Society" Advisory P. The 2022 hormone therapy position statement of The North American menopause society. Menopause. 2022;29(7):767–94. https://doi.org/10.1097/GME.0000000000002028.CrossRef

21.

Chlebowski RT, Aragaki AK. The Women’s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Menopause. 2023;30(4):454–61. https://doi.org/10.1097/GME.0000000000002154.CrossRefPubMed

22.

Abenhaim HA, Suissa S, Azoulay L, Spence AR, Czuzoj-Shulman N, Tulandi T. Menopausal hormone therapy formulation and breast cancer risk. Obstet Gynecol. 2022;139(6):1103–10. https://doi.org/10.1097/AOG.0000000000004723.CrossRefPubMed

23.

Boughey JC, Hartmann LC, Anderson SS, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol. 2010;28(22):3591–6. https://doi.org/10.1200/JCO.2010.28.0784.CrossRefPubMedPubMedCentral

24.

Pankratz VS, Hartmann LC, Degnim AC, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;26(33):5374–9. https://doi.org/10.1200/JCO.2007.14.8833.CrossRefPubMedPubMedCentral

25.

Tice JA, Bissell MCS, Miglioretti DL, et al. Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat. 2019;175(2):519–23. https://doi.org/10.1007/s10549-019-05167-2.CrossRefPubMedPubMedCentral

26.

Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V, Thakkinstian A. Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat. 2012;133(1):1–10. https://doi.org/10.1007/s10549-011-1853-z.CrossRefPubMed

27.

Mavaddat N, Michailidou K, Dennis J, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104(1):21–34. https://doi.org/10.1016/j.ajhg.2018.11.002.CrossRefPubMed

28.

Mbuya-Bienge C, Pashayan N, Kazemali CD, Lapointe J, Simard J, Nabi H. A systematic review and critical assessment of breast cancer risk prediction tools incorporating a polygenic risk score for the general population. Cancers. 2023;15(22):5380. https://doi.org/10.3390/cancers15225380.CrossRefPubMedPubMedCentral

29.

Barnes DR, Rookus MA, McGuffog L, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020;22(10):1653–66. https://doi.org/10.1038/s41436-020-0862-x.CrossRefPubMedPubMedCentral

30.

Mavaddat N, Ficorella L, Carver T, et al. Incorporating alternative polygenic risk scores into the BOADICEA breast cancer risk prediction model. Cancer Epidemiol Biomarkers Prev. 2023;32(3):422–7. https://doi.org/10.1158/1055-9965.EPI-22-0756.CrossRefPubMedPubMedCentral

31.

Bevers TB, Niell BL, Baker JL, et al. NCCN Guidelines® insights: breast cancer screening and diagnosis, version 1.2023: featured updates to the NCCN guidelines. J Nat Compr Cancer Netw. 2023;21(9):900–9. https://doi.org/10.6004/jnccn.2023.0046.CrossRef

32.

Kontos D, Winham SJ, Oustimov A, et al. Radiomic phenotypes of mammographic parenchymal complexity: toward augmenting breast density in breast cancer risk Assessment. Radiology. 2019;290(1):41–9. https://doi.org/10.1148/radiol.2018180179.CrossRefPubMed

33.

Vachon CM, Scott CG, Norman AD, et al. Impact of artificial intelligence system and volumetric density on risk prediction of interval, screen-detected, and advanced breast cancer. J Clin Oncol. 2023. https://doi.org/10.1200/JCO.22.01153.CrossRefPubMedPubMedCentral

34.

Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89. https://doi.org/10.3322/canjclin.57.2.75.CrossRefPubMed

35.

Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2016;164(4):268–78. https://doi.org/10.7326/M15-17894.CrossRefPubMedPubMedCentral

36.

Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;2013(6):CD001877. https://doi.org/10.1002/14651858.CD001877.pub5.CrossRefPubMedPubMedCentral

37.

Bakker MF, de Lange SV, Pijnappel RM, et al. Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med. 2019;381(22):2091–102. https://doi.org/10.1056/NEJMoa1903986.CrossRefPubMed

38.

Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427–37. https://doi.org/10.1056/NEJMoa031759.CrossRefPubMed

39.

Bevers TB, Anderson BO, Bonaccio E, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060–96. https://doi.org/10.6004/jnccn.2009.0070.CrossRefPubMed

40.

Laws A, Katlin F, Hans M, et al. Screening MRI does not increase cancer detection or result in an earlier stage at diagnosis for patients with high-risk breast lesions: a propensity score analysis. Ann Surg Oncol. 2023;30(1):68–77. https://doi.org/10.1245/s10434-022-12568-z.CrossRefPubMed

41.

Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol. 2014;32(22):2304–10. https://doi.org/10.1200/JCO.2013.52.5386.CrossRefPubMed

42.

Comstock CE, Gatsonis C, Newstead GM, et al. Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA. 2020;323(8):746–56. https://doi.org/10.1001/jama.2020.0572.CrossRefPubMedPubMedCentral

43.

Baxter GC, Selamoglu A, Mackay JW, Bond S, Gray E, Gilbert FJ. A meta-analysis comparing the diagnostic performance of abbreviated MRI and a full diagnostic protocol in breast cancer. Clin Radiol. 2021;76(2):154.e23-154.e32. https://doi.org/10.1016/j.crad.2020.08.036.CrossRefPubMed

44.

Hernandez ML, Osorio S, Florez K, Ospino A, Diaz GM. Abbreviated magnetic resonance imaging in breast cancer: a systematic review of literature. Eur J Radiol Open. 2021;8:100307. https://doi.org/10.1016/j.ejro.2020.100307.CrossRefPubMed

45.

Potsch N, Vatteroni G, Clauser P, Helbich TH, Baltzer PAT. Contrast-enhanced mammography versus contrast-enhanced breast MRI: a systematic review and meta-analysis. Radiology. 2022;305(1):94–103. https://doi.org/10.1148/radiol.212530.CrossRefPubMed

46.

Phillips J, Mehta TS, Portnow LH, Fishman MDC, Zhang Z, Pisano ED. Comparison of contrast-enhanced mammography with MRI utilizing an enriched reader study: a breast cancer study (CONTRRAST Trial). Radiology. 2023;309(2):e230530. https://doi.org/10.1148/radiol.230530.CrossRefPubMed

47.

Practice Bulletin Number 179: Breast cancer risk assessment and screening in average-risk women. Obstet Gynecol. 2017;130(1):e1-e16. doi:https://doi.org/10.1097/AOG.0000000000002158

48.

Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American cancer society. JAMA. 2015;314(15):1599–614. https://doi.org/10.1001/jama.2015.12783.CrossRefPubMedPubMedCentral

Title: Following the High-Risk Patient: Breast Cancer Risk-Based Screening
Authors: Christine L. Klassen, MD
Lyndsay D. Viers, MD
Karthik Ghosh, MD
Publication date: 01-02-2024
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Published in: Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-14957-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Following the High-Risk Patient: Breast Cancer Risk-Based Screening

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions

Variation in Hospital Mortality After Complex Cancer Surgery: Patient, Volume, Hospital or Social Determinants?

Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress?

ASO Visual Abstract: Robotic Versus Thoracoscopic Sub-lobar Resection for Octogenarians with Clinical IA-Stage Non-small Cell Lung Cancer: A Propensity Score-Matched Real-World Study

ASO Visual Abstract: Intra- and Interpatient Drug Response Heterogeneity Exist in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Non-gynecologic Cancers

ASO Author Reflections: Prediction of Morbidity and Mortality After Esophagectomy: A Systematic Review